Skip to content


  • Oral presentation
  • Open Access

Immune activation and MRgFUS

  • Katherine Ferrara1,
  • Elizabeth Ingham1,
  • Andrew Wong1,
  • Azadeh Kheirolomoom1,
  • Brett Fite1,
  • Yu Liu1,
  • Lisa Mahakian1 and
  • Sarah Tam1
Journal of Therapeutic Ultrasound20153(Suppl 1):O41

Published: 30 June 2015


Public HealthFuture StudyDendritic CellSystemic DiseaseImmune Activation


For many years, immune activation following tumor ablation has been evaluated in the treatment of systemic cancer. Ultrasound ablation is thought to promote dendritic cell maturation and T-cell immunity, and is particularly advantageous because it is non-invasive, can be controlled with high spatial precision and uses no harmful ionizing radiation.


Recently, immune adjuvants have been shown to be effective in treating metastatic cancer, with cancer immunotherapy named as the “breakthrough of the year” in 2013. At this time, combining ablation with immune adjuvants is a promising technique for expanding the utility of ultrasound for the treatment of systemic disease. We will briefly review the status of this combined therapy and opportunities for future studies.

Authors’ Affiliations

University of California Davis, Davis, United States


© Ferrara et al; licensee BioMed Central Ltd. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.